NCT04131192 is a Phase 1 clinical trial of Z650 in Pancreatic Cancer, sponsored by Sunshine Lake Pharma Co., Ltd..

Who is sponsoring NCT04131192?

NCT04131192 is sponsored by Sunshine Lake Pharma Co., Ltd..

What drugs are being tested in NCT04131192?

Interventions in NCT04131192: Z650, Gemcitabine.

What condition does NCT04131192 study?

NCT04131192 studies Pancreatic Cancer.

Is NCT04131192 still recruiting?

NCT04131192 is currently terminated. Last updated 6 May 2022.

Last reviewed 2022-05-06 · How we verify

NCT04131192

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

Terminated Phase 1 Last updated 6 May 2022

What this trial tests

Phase 1 trial testing Z650 in Pancreatic Cancer in 13 participants. Terminated before completion.

Timeline

11 November 2019

Primary endpoint
9 September 2021

9 September 2021

Quick facts

Lead sponsor	Sunshine Lake Pharma Co., Ltd.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	11 November 2019
Primary completion	9 September 2021
Estimated completion	9 September 2021
Sites	2 locations across China

Drugs / interventions tested

Z650 — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Sunshine Lake Pharma Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.
Amelia T, Kartasasmita RE, Ohwada T, Tjahjono DH. · · 2022 · cited 83× · PMID 35164092 · DOI 10.3390/molecules27030819
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma.
Rudloff U. · · 2022 · cited 9× · PMID 36250721 · DOI 10.1080/14728214.2022.2134346

Verify or expand the search:

Other trials of Z650

Trials testing the same drug.

NCT03888092 — Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification · Phase 1, PHASE2 · completed

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Sunshine Lake Pharma Co., Ltd. trials

Trials by the same sponsor.

NCT07341672 — A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itrac · Phase 1 · not yet recruiting
NCT05048368 — Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function · Phase 1 · not yet recruiting
NCT07376200 — Single-ascending Dose Study of HEC-151 Injection · Phase 1 · not yet recruiting
NCT07082842 — Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF · Phase 3 · not yet recruiting
NCT07211165 — Clinical Study on the Mass Balance of Clifutinib · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04131192 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sunshine Lake Pharma Co., Ltd.
Last refreshed: 6 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04131192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing